CUMBERLAND PHARMACEUTICALS INC
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
CPIX$5.22+4.2%Stored close · as of Nov 6, 2026
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2025-06-30; filed 2025-08-08.
0001628280-25-039326
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2025-09-30; filed 2025-11-07.
0001087294-25-000020
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 137 previous paragraphs and 143 current paragraphs.
66 unchanged; 49 reworded; 27 added; 20 removed; 2 previous and 1 current paragraphs rearranged.
Tables are not compared: 12 previous and 14 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (27)
Current report
•Talicia® (omeprazole magnesium, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection.
Current report
New Product Added to Commercial Product Portfolio
Current report
We recently announced arrangements with RedHill Biopharma Ltd. (“RedHill”) to jointly commercialize Talicia®, adding the brand to our commercial product portfolio. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults, a bacterial infection and leading risk factor for gastric cancer. Talicia net revenues were $8 million in 2024.
Current report
We have formed a new company with RedHill named Talicia Holdings, Inc. RedHill has assigned all its Talicia related assets to the new company for a 70% ownership position. Cumberland will provide $4 million in investment capital over a two-year period and receive ownership of the 30% remaining shares. Cumberland and RedHill have equal board seats and voting rights in the new company, and these arrangements will enable Cumberland to participate in the value it helps create in the brand. RedHill has also assigned to the new company the international rights to Talicia including existing international licensing agreements, and Cumberland will therefore also benefit from those arrangements, through its 30% ownership.
Current report
Through a co-commercialization agreement, we will assume responsibility for the distribution and sale of Talicia in the U.S. Cumberland will record Talicia product sales and equally share Talicia’s net revenues. We will also provide an annual investment of up to $2 million to cover certain distribution, marketing and sales costs. Cumberland will lead the sales promotion for Talicia and will leverage our established field national sales division, which has been detailing Kristalose, to increase the number of patients benefiting from Talicia. The new company will provide operational support with responsibility for the product’s marketing, manufacturing, regulatory and supply chain functions.
Current report
Talicia is the only all-in-one treatment containing omeprazole, amoxicillin and rifabutin, and is now recommended as a first-line therapy in the American College of Gastroenterology (ACG) clinical guidelines. Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation.
Current report
In October 2025, our ibuprofen injection product received regulatory approval in Mexico. We previously announced our partnership with PiSA Farmaceutica, a well-established Mexican pharmaceutical firm. Under the agreement, PiSA is provided with the exclusive supply and distribution rights for the ibuprofen product in the Mexican market while Cumberland provides regulatory and manufacturing support. PiSA plans to introduce the product in 800 mg vials, making it accessible for a variety of clinical uses in Mexican healthcare facilities.
Current report
Vibativ® Added to Premier National Group Purchasing Agreement
Current report
In October 2025, we announced that Vibativ was added to a national group purchasing agreement with Premier, Inc. The product addition allows Premier members to purchase Vibativ, in the 12-vial carton and 4-vial Starter Pak. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 325,000 other providers and organizations. With expanded access, Premier member healthcare providers now have greater flexibility in ordering Vibativ for both inpatient and outpatient settings.
Current report
This year, we announced positive top-line results from our FIGHT DMD clinical trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it is the first successful Phase 2 study specifically targeting the cardiac complications of their condition. Ifetroban has been studied in over 1,400 subjects across multiple clinical trials, demonstrating a well-established safety profile.
Current report
The trial enrolled 41 DMD patients who received either low dose ifetroban (150 mg per day), high dose ifetroban (300 mg per day) or placebo. The study's primary endpoint was an improvement in the heart's left ventricular ejection fractions (LVEF). Key findings included:
Current report
•High dose ifetroban treatment resulted in an overall 3.3% improvement in LVEF;
Current report
•The high dose ifetroban group showed an increase in 1.8% in LVEF, while the study placebo group showed an expected decline in LVEF of 1.5%;
Current report
•When compared with propensity matched natural history controls, the difference was even more pronounced, with the high dose treatment providing a significant 5.4% overall improvement in LVEF, as the control patients experienced a 3.6% decline in LVEF; and
Current report
•Both doses of ifetroban were well-tolerated, with no serious drug-related events.
Current report
Net revenues. The net revenues for the three months ended September 30, 2025, were $8.3 million compared to $9.1 million for the three months ended September 30, 2024.
Current report
Caldolor revenue was $0.9 million for the third quarter of 2025, compared to $1.3 million for the third quarter of 2024. The decrease was primarily due to a delay in the manufacturing and shipment of an international order for the product.
Current report
Other revenue was $0.3 million for the three months ended September 30, 2025, compared to $0.6 million for the three months ended September 30, 2024. The decrease was primarily due to less CET revenues for the period.
Current report
Research and development. The research and development costs for the three months ended September 30, 2025 and 2024, were similar at $1.3 million for both periods.
Current report
(1)Net revenue includes $14,689 related to additional international training revenue.
Current report
(2)The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.
Current report
Research and Development Expenses
Current report
The following table shows the primary components of our research and development expenses for the three months ended September 30, 2025 and 2024.
Current report
Nine months ended September 30, 2025 compared to the nine months ended September 30, 2024
Current report
Vibativ revenue was $6.7 million for the nine months ended September 30, 2025, and $5.1 million for the nine months ended September 30, 2024. The increase in net revenue of the product was due to higher sales volumes, including growing shipments of the product's 4-Pak.
Current report
Research and Development Expenses
Current report
The following table shows the primary components of our research and development expenses for the nine months ended September 30, 2025 and 2024.
Removed paragraphs (20)
Previous report
In June 2025, breakthrough findings from our Phase II FIGHT DMD trial, evaluating our ifetroban product candidate in patients with Duchenne muscular dystrophy ("DMD"), were presented at the Parent Project Muscular Dystrophy Annual Conference. The findings demonstrated that high-dose ifetroban delivered a 5.4% improvement in cardiac function in patients with DMD. The presentation also included additional biomarker data indicating reduced cardiac damage, which correlated with the clinical findings. These results position ifetroban as a potential treatment for DMD cardiomyopathy—the leading cause of death in these patients and a critical unmet medical need affecting 90% of DMD patients by age 18.
Previous report
In June 2025, we completed the comprehensive analysis of the study results, completed our clinical study report and submitted it to the FDA along with a request for an end-of-Phase 2 meeting. Following the FDA’s prompt response, we are scheduled to meet with them this fall to discuss our clinical program and development pathway.
Previous report
Pharmacokinetic Analysis Reinforces Vibativ®Dosing Strategies
Previous report
A comprehensive new pharmacokinetic analysis of Vibativ was published in Antimicrobial Agents and Chemotherapy in June 2025. The analysis utilizes data from over 1,200 patients across varied demographics and comorbidity profiles. The findings support optimized dosing strategies for patients with different infection severities and renal function levels, reinforcing Vibativ’s critical role in treating life-threatening gram-positive infections.
Previous report
New Study Features Caldolor® (ibuprofen injection) for Older Patients
Previous report
In May 2025, we announced the publication of our study investigating Caldolor (intravenous ibuprofen) in Clinical Therapeutics, demonstrating the product’s safety and efficacy for managing post-operative pain in patients 60 years of age and older. The analysis, encompassing over 1,000 older patients from our comprehensive post-surgical studies, represents the first such evaluation in this vulnerable population, where traditional pain management options such as opioids carry increased risk.
Previous report
The analysis was performed using data from four prospective clinical studies in which Caldolor was administered for the treatment of pain and/or fever in hospitalized patients. The efficacy analysis included 591 patients from two placebo-controlled trials, with safety assessed across all 1,041 patients. Caldolor treatment resulted in a 24% reduction in pain at rest (p=0.008) and a 20% reduction in pain with movement (p=0.001) between 6- and 24-hours post-surgery compared with placebo. The study showed that Caldolor treatment led to a 23.2% reduction in total post-operative morphine requirement (p=0.031) compared with placebo. The incidence of adverse events was lower in Caldolor-treated patients compared to placebo (55% vs 90% in older patients).
Previous report
Pain management in older patients presents unique challenges due to their increased sensitivity to opioid analgesics and higher risk of side effects. Nearly one-third of all ambulatory surgeries are performed on older patients, yet this population is often underrepresented in clinical trials, highlighting an important medical need addressed in this study. The study marks an important advancement in pain management for older individuals, as it is one of the first studies specifically evaluating Caldolor in this vulnerable population.
Previous report
Qureight Partnership for AI-Enhanced IPF Trial
Previous report
In May 2025, we announced a partnership with Qureight Ltd., a core imaging laboratory developing deep-learning image analytics based in Cambridge U.K., to enhance the outcome and output of data from our FIGHTING FIBROSIS™ clinical trial. The partnership will utilize Qureight's advanced, deep-learning image analytics tools for complex lung disease applications to provide deeper insights into treatment efficacy and disease progression in Cumberland's IPF clinical program.
Previous report
Under this partnership, Qureight's AI-driven analytics technologies will be used to quantify changes in multiple imaging biomarkers, using computed tomography (CT) data from study patients. Qureight's quantitative deep learning-based tools will precisely measure changes in the volume of patients' fibrotic, vascular and airway lung compartments, allowing a more detailed investigation of ifetroban's modulation of both lung structure and function. The collaboration leverages Qureight's expertise in IPF and quantitative imaging biomarkers to support Cumberland's evaluation of crucial primary and secondary study endpoints.
Previous report
We continue to support our international partners in their efforts to register Vibativ in their countries.
Previous report
On April 16, 2025, the U.S. Department of Commerce announced an investigation under Section 232 of the Trade Expansion Act of 1962 into imports of pharmaceuticals and pharmaceutical ingredients, including finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients, and key starting materials, and derivative products of those items. The investigation will examine the impact of these imports on U.S. national security culminating in a decision by the President whether to take action to remedy any identified threats, including by imposing additional tariffs. The statute provides that the Commerce Department report must be completed within 270 days of initiation of the investigation and that the President must decide whether to act within 90 days of receiving the report.
Previous report
Based on the trade deal reached between the U.S. and the European Union in late July 2025, a 15 percent tariff will be imposed on imported medicines from Europe into the U.S.
Previous report
Net revenues. Net revenues for the three months ended June 30, 2025, were $10.8 million compared to $9.8 million for the three months ended June 30, 2024. As detailed in the table above, net revenue increased primarily due to four of our marketed products during the second quarter of 2025 - Sancuso, Vibativ, Caldolor and Acetadote.
Previous report
Caldolor revenue was $1.6 million for the second quarter of 2025, compared to $0.8 million for the second quarter of 2024. The increase results from higher international sales in 2025.
Previous report
Other revenue was $0.5 million for the three months ended June 30, 2025, compared to $0.2 million for the three months ended June 30, 2024. The increase results from payments received for a research contract.
Previous report
(1)The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.
Previous report
Six months ended June 30, 2025 compared to the six months ended June 30, 2024
Previous report
Vibativ revenue was $4.1 million for the six months ended June 30, 2025, and the six months ended June 30, 2024.
Reworded paragraphs (49)
Previous wording
•Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
Current wording
•Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
Previous wording
•Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Current wording
•Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and
Previous wording
In addition to these commercial brands, we recently completed a Phase II study in patients with cardiomyopathy associated with Duchenne muscular dystrophy(“DMD”). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.
Current wording
In addition to these commercial brands, we have announced breakthrough results in clinical study of our ifetroban product candidate in patients with cardiomyopathy associated with Duchenne muscular dystrophy(“DMD”). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. We then completed and submitted a clinical study report to the FDA and began interactions to determine their remaining development requirements.
Previous wording
Cumberland has built core competencies for the acquisition, development and commercialization of pharmaceutical products in the U.S., and we believe we can leverage this existing infrastructure to support our continued growth. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory, manufacturing, sales, marketing and finance.
Current wording
Cumberland has built core competencies for the acquisition, development and commercialization of pharmaceutical products in the U.S., and we can leverage this existing infrastructure to support our continued growth. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory, manufacturing, sales, marketing and finance.
Previous wording
Cumberland’s growth strategy involves maximizing the potential of our existing brands, while continuing to build a portfolio of differentiated products. We currently own six products approved by the FDA in the United States. We are also building international partnerships to bring our medicines to patients in other countries. Additionally, we look for opportunities to expand our brands into new patient populations through clinical trials, new product presentations and our support of select, investigator-initiated studies. Meanwhile, our clinical team is developing a pipeline of new product candidates to address poorly met medical needs. We also pursue opportunities to acquire additional marketed brands, as well as late-stage development product candidates in our target medical specialties.
Current wording
Additionally, we look for opportunities to expand our brands into new patient populations through clinical trials, new product presentations and our support of select, investigator-initiated studies. Meanwhile, our clinical team is developing a pipeline of new product candidates to address poorly met medical needs. We also pursue opportunities to acquire additional marketed brands, as well as late-stage development product candidates in our target medical specialties.
Previous wording
We have also shared a new partnership with Saudi Arabia-based Tabuk Pharmaceutical to introduce Vibativ into the Middle East. The arrangement provided Tabuk exclusive rights to distribute Vibativ in Saudi Arabia and Jordan, with the option to expand into other countries in the region. Tabuk has obtained the final approvals needed to commercialize Vibativ in Saudi Arabia. In late 2024, we began shipping Vibativ there and completed the needed training to launch the product in that country.
Current wording
During the third quarter of 2025, we announced the launch of Vibativ® in Saudi Arabia. The product launch follows an agreement with Tabuk Pharmaceutical Manufacturing Company to introduce Vibativ into the Middle East. The arrangement provided Tabuk exclusive rights to distribute Vibativ in Saudi Arabia and Jordan, with the option to expand into other countries in the region. Tabuk has obtained the final approvals needed to commercialize Vibativ in Saudi Arabia.
Previous wording
We previously announced our potent antibiotic Vibativ received approval from the regulatory authorities in China. That milestone provides us with access to the world’s second-largest pharmaceutical market – and we look forward to the launch of our product there.
Current wording
Additionally, we previously announced that Vibativ received approval from the regulatory authorities in China. That milestone provides us with access to the world’s second-largest pharmaceutical market, and we look forward to the launch of our product there.
Previous wording
In July 2025, we announced the availability of the Vibativ (telavancin) 4-Vial Starter Pak through a new supply arrangement with Vizient Inc., making it accessible to their healthcare providers nationwide.
Current wording
Earlier this year, we announced the availability of the Vibativ (telavancin) 4-Vial Starter Pak through a new supply arrangement with Vizient Inc., making it accessible to their healthcare providers nationwide.
Previous wording
The top-line FIGHT DMD study findings were also selected for a late-breaking presentation at the Muscular Dystrophy Association’s Clinical & Scientific Conference in March 2025.
Current wording
The top-line findings from our FIGHT DMD study were featured as a late-breaking presentation at the Muscular Dystrophy Association's Clinical & Scientific Conference in March 2025 and subsequently presented at the Parent Project Muscular Dystrophy Annual Conference in June 2025. Following these presentations, we completed our comprehensive analysis and submitted the clinical study report to the FDA with a request for an end-of-Phase 2 meeting. This meeting took place in September 2025, where we discussed remaining clinical development and manufacturing requirements. The FDA has recommended a follow-up meeting, which we are currently planning.
Previous wording
In addition, we have a Phase II clinical study, the FIGHTING FIBROSIS™ trial, underway in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. Patient enrollment is now well underway in medical centers across the U.S. The study design includes both an interim safety analysis, as well as an interim efficacy analysis.
Current wording
Meanwhile, we have been evaluating our ifetroban product candidate in a Phase II clinical program in patients with Systemic Sclerosis (SSc) or scleroderma. Enrollment in the study was completed this year, and we are monitoring the clinical sites in preparation to lock the database and begin evaluating the results. We look forward to announcing top-line findings from this study this year. In addition, we have a Phase II clinical study, the FIGHTING FIBROSIS™ trial, underway in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. Patient enrollment is now well underway in medical centers across the U.S. The study design includes both an interim safety analysis, as well as an interim efficacy analysis.
Previous wording
We have also completed a pilot Phase II study involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure, 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients with Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. There was no significant safety issues identified with the use of ifetroban in these patients. Additional pilot studies of ifetroban are underway, through several investigator-initiated trials. We are awaiting results from the various studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.
Current wording
We have also completed a pilot Phase II study involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure, 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients with Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. There was no significant safety issues identified with the use of ifetroban in these patients. Additional pilot studies of ifetroban are underway, through several investigator-initiated trials. Following completion of our ongoing studies and FDA feedback, we will determine the optimal regulatory pathways for ifetroban, our first new chemical entity.
Previous wording
• intellectual property and other exclusivity rights;
Current wording
• intellectual property and other exclusive rights;
Previous wording
Kristalose is a dry powder crystalline prescription formulation of lactulose indicated for the treatment of constipation. The U.S. constipation therapy market includes various prescription and over the counter ("OTC") products. There are several branded prescription products which we believe are our primary competitors including Amitiza®, Movantik®, Linzess® and Vibrant®.
Current wording
Kristalose is a dry powder crystalline prescription formulation of lactulose indicated for the treatment of constipation. The U.S. constipation therapy market includes various prescription and over the counter, or OTC, products. There are several branded prescription products which we believe are our primary competitors including Amitiza®, Movantik®, Linzess® and Vibrant®.
Previous wording
The United States and other countries have recently begun imposing new tariffs on international trade. While pharmaceuticals have been largely exempt from these recently imposed U.S. tariffs, such exemptions may be removed in the future. We continue to monitor and evaluate the impacts of tariffs on our business and the results of our operations.
Current wording
The United States and other countries have recently begun imposing new tariffs on international trade. While pharmaceuticals have been largely exempt from these recently imposed U.S. tariffs, such exemptions may be removed in the future. We continue to monitor and evaluate the impact of tariffs on our business and the results of our operations.
Previous wording
Kristalose revenue was $2.8 million for the second quarter of 2025 and $4.1 million for the same period in the prior year. The decrease was the result of lower sales volume.
Current wording
Kristalose revenue was $1.2 million for the third quarter of 2025 and $3.6 million for the same period in the prior year. The decrease was the result of lower sales volume primarily due to a delay in shipments of our Authorized Generic product, in addition to increased generic substitution.
Previous wording
Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the second quarter of 2025, there was an increase of $0.2 million in the product's revenue when compared to the prior year period due to an increase of our branded and Authorized Generic sales.
Current wording
Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the third quarter of 2025, there was an increase of $0.1 million in the product's revenue when compared to the prior year period due to an increase in our Authorized Generic sales.
Previous wording
There were no Vaprisol branded product sales for the second quarter of 2025 as Cumberland is currently out of inventory of the product as we await FDA approval on a new manufacturer. The amount represents charges for normal sales deduction adjustments.
Current wording
There were no Vaprisol branded product sales for the third quarter of 2025 as Cumberland is currently out of inventory of the product as we await FDA approval on a new manufacturer. The amount represents adjustments of deductions from previous sales of the product.
Previous wording
Vibativ revenue was $2.7 million for the three months ended June 30, 2025, and $2.5 million for the same prior year period. The increase in net revenue of the product was due to higher sales volume.
Current wording
Vibativ revenue was $2.6 million for the three months ended September 30, 2025, and $1.0 million for the same prior year period. The increase in net revenue of the product was due to higher sales volumes, including growing shipments of the product's 4-Pak.
Previous wording
Sancuso revenue was $3.1 million for the second quarter of 2025, compared to $2.2 million for the second quarter of 2024 resulting in an increase of $0.9 million. The increase resulted primarily from increased shipments as well as lower sales deductions associated with the product for the second quarter of 2025.
Current wording
Sancuso revenue was $3.2 million for the third quarter of 2025, compared to $2.6 million for the third quarter of 2024 resulting in an increase of $0.6 million. The increase resulted primarily from increased shipments as well as lower sales deductions associated with the product.
Previous wording
Cost of products sold. Cost of products sold for the second quarter of 2025 and 2024 were $2.0 million and $1.7 million, respectively. Cost of products sold, as a percentage of net revenues, were 18.6% during the three months ended June 30, 2025, compared to 17.4% during the three months ended June 30, 2024. The unfavorable percentage increase is primarily due to higher international sales in 2025 which typically incur higher cost of goods sold as a percentage relative to the lower international revenue on a per unit basis.
Current wording
Cost of products sold. The cost of products sold for the third quarter of 2025 and 2024 were $1.0 million and $1.3 million, respectively. Cost of products sold, as a percentage of net revenues, were 11.9% during the three months ended September 30, 2025, compared to 14.6% during the three months ended September 30, 2024. The favorable percentage decrease is primarily due to the higher international sales in 2024, which typically have lower gross margin.
Previous wording
Selling and marketing. Selling and marketing expenses for the second quarter of 2025 were similar when compared to the same period last year.
Current wording
Selling and marketing. The selling and marketing expenses for the third quarter of 2025 and 2024, were similar at $4.4 million for both periods.
Previous wording
General and administrative. General and administrative expense for the second quarter of 2025 was $2.9 million compared to $2.8 million for the same period in 2024. The increase is due to higher compensation expenses.
Current wording
General and administrative. The general and administrative expense for the third quarter of 2025 was $2.6 million compared to $2.7 million for the same period in 2024. The decrease is due to lower corporate life insurance expense.
Previous wording
Amortization. Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs. Amortization for the three months ended June 30, 2025 and 2024, totaled approximately $1.0 million and $1.1 million, respectively.
Current wording
Amortization. The amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs. Amortization for the three months ended September 30, 2025 and 2024, totaled approximately $1.0 million and $1.1 million, respectively.
Previous wording
Income taxes. Income tax expense for the three months ended June 30, 2025 and for the three months ended June 30, 2024 was less than $0.01 million for each year.
Current wording
Income taxes. The income tax expense for the three months ended September 30, 2025, and for the three months ended September 30, 2024 was less than $0.01 million for each year.
Previous wording
The following table presents the unaudited interim statements of operations for continuing operations for the six months ended June 30, 2025 and 2024:
Current wording
The following table presents the unaudited interim statements of operations for continuing operations for the nine months ended September 30, 2025 and 2024:
Previous wording
Net revenues. Net revenues for the six months ended June 30, 2025, were $22.6 million compared to $18.3 million for the six months ended June 30, 2024, an increase of $4.2 million.
Current wording
Net revenues. The net revenues for the nine months ended September 30, 2025, were $30.8 million compared to $27.4 million for the nine months ended September 30, 2024, an increase of $3.4 million.
Previous wording
Kristalose revenue was $6.2 million during the first six months of 2025, compared to $7.3 million for the prior year period. Revenue decreased due to the result of lower sales volume.
Current wording
Kristalose revenue was $7.4 million during the first nine months of 2025, compared to $10.9 million for the prior year period. The decrease was the result of lower sales volume primarily due to a delay in shipments of our Authorized Generic product, in addition to increased generic substitution..
Previous wording
Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the six months ended June 30, 2025, there was an increase of $0.2 million in the product's revenue when compared to the prior year period due to an increase in sales for our Authorized Generic.
Current wording
Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the nine months ended September 30, 2025, there was an increase of $0.3 million in the product's revenue when compared to the prior year period due to an increase in sales for our Authorized Generic.
Previous wording
Sancuso revenue was $5.4 million for the six months ended June 30, 2025, compared to $4.0 million for the same period last year. The increase resulted primarily from increased sales and reduced sales deductions.
Current wording
Sancuso revenue was $8.6 million for the nine months ended September 30, 2025, compared to $6.6 million for the same period last year. The increase resulted primarily from increased shipments, as well as lower sales deductions associated with the product.
Previous wording
There were no Vaprisol branded product sales for the six months ended June 30, 2025 and the amounts noted were for normal sales deduction adjustments. Revenue for the six months ended June 30, 2024, were related to the sales of our compounded product.
Current wording
There were no Vaprisol branded product sales for the nine months ended September 30, 2025 and 2024. The amount represents adjustments of deductions from previous sales of the product.
Previous wording
Omeclamox-Pak had no sales for the six months ended June 30, 2025 and 2024, as Cumberland is currently out of commercial inventory of this product. The amounts noted resulted from normal distribution adjustments.
Current wording
Omeclamox-Pak had no sales for the nine months ended September 30, 2025 and 2024. The amount represents adjustments of deductions from previous sales of the product.
Previous wording
Caldolor revenue was $2.9 million for the six months ended June 30, 2025, an increase of $0.6 million over the same period in 2024 primarily due to international shipments.
Current wording
Caldolor revenue was $3.8 million for the nine months ended September 30, 2025, an increase of $0.2 million over the same period in 2024 primarily due to an increase in international shipments.
Previous wording
Other revenue was $3.6 million for the six months ended June 30, 2025, representing a $3.1 million increase from the same period in 2024, as a result of a milestone payment received in 2025.
Current wording
Other revenue was $3.9 million for the nine months ended September 30, 2025, representing a $2.8 million increase from the same period in 2024, primarily as a result of a milestone payment received in 2025.
Previous wording
Cost of products sold. Cost of products sold for the first six months of 2025 were $3.4 million, consistent when compared to $3.3 million for the first six months of 2024.
Current wording
Cost of products sold. The cost of products sold for the first nine months of 2025 was $4.4 million, consistent with the $4.6 million for the first nine months of 2024.
Previous wording
Selling and marketing. Selling and marketing expense for the six months ended June 30, 2025, increased $0.1 million compared to the prior year period. This increase is primarily attributable to the timing of the expenditures.
Current wording
Selling and marketing. The selling and marketing expense for the nine months ended September 30, 2025, increased $0.1 million compared to the prior year period. This slight increase is primarily attributable to the timing of the expenditures.
Previous wording
Research and development. Research and development costs were $2.8 million for the first six months of 2025 compared to $2.2 million for the same period last year. A portion of our research and development costs is variable as we continue to fund the ongoing clinical initiatives associated with our pipeline product candidates. These variable costs depend on the number of active trials, study sites and patients as well as the cost per patient in each of our clinical programs.
Current wording
Research and development. The research and development costs were $4.0 million for the first nine months of 2025 compared to $3.5 million for the same period last year. A portion of our research and development costs is variable as we continue to fund the ongoing clinical initiatives associated with our pipeline product candidates. These variable costs depend on the number of active trials, study sites and patients as well as the cost per patient in each of our clinical programs.
Previous wording
General and administrative. General and administrative expense for the six months ended June 30, 2025, increased to $5.3 million compared to $5.1 million during the six months ended June 30, 2024. The increase is due to higher salaries and contract labor costs.
Current wording
General and administrative. The general and administrative expenses for the nine months ended September 30, 2025, was $7.9 million compared to $7.8 million during the nine months ended September 30, 2024. This slight increase is due to higher salary expense in 2025.
Previous wording
(1)Net revenue includes $2,975,000 related to a milestone payment received in 2025.
Current wording
(1)Net revenue includes $2,989,689 related to a milestone payment received in 2025 along with other product related revenue.
Previous wording
(1) Net revenue includes a $1,000,000 payment to Cumberland related to a settlement agreement of milestone payments, $1,288 of other income and $2,975,000 related to a milestone payment.
Current wording
(1) Net revenue includes a $1,000,000 payment to Cumberland related to a settlement agreement of milestone payments, $15,978 of other income and $2,975,000 related to a milestone payment.
Previous wording
Amortization. Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs. Amortization for the six months ended June 30, 2025, and six months ended June 30, 2024, totaled approximately $2.0 million and $2.2 million, respectively. The decrease was attributable to a reduction to the valuation of the Acetadote intangible asset recognized in December 2024.
Current wording
Amortization. The amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs. Amortization for the nine months ended September 30, 2025, and nine months ended September 30, 2024, totaled approximately $3.0 million and $3.3 million, respectively. The decrease was attributable to a reduction to the valuation of the Acetadote intangible asset recognized in December 2024.
Showing the first 40 of 49 pairs. Open the source sections for the rest.
Rearranged current paragraphs (1)
Current report — wording carried from elsewhere
Cumberland’s growth strategy involves maximizing the potential of our existing brands, while continuing to build a portfolio of differentiated products. We currently own rights to seven products approved by the FDA in the United States. We are also building international partnerships to bring our medicines to patients in other countries.
Rearranged previous paragraphs (2)
Previous report — wording carried elsewhere
Meanwhile, we have been evaluating our ifetroban product candidate in a Phase II clinical program in patients with Systemic Sclerosis or scleroderma. Enrollment in the study was completed this year, and we are monitoring the clinical sites in preparation to lock the database and begin evaluating the results. We expect to announce top-line findings from this study later this year.
Previous report — wording carried elsewhere
Research and development. Research and development costs for the second quarter of 2025 were $1.5 million compared to $1.1 million for the same period in 2024. The increase is primarily due to a portion of our research and development costs that are variable as we continue to fund the ongoing clinical initiatives associated with our pipeline product candidates. These variable costs depend on the number of active trials, study sites and patients as well as the cost per patient in each of our clinical programs.